Michele Janis - 10 Jun 2022 Form 3 Insider Report for OptiNose, Inc. (OPTN)

Role
Acting Chief Financial Officer
Signature
/s/ Anthony Krick, Attorney-in-Fact
Issuer symbol
OPTN
Transactions as of
10 Jun 2022
Net transactions value
$0
Form type
3
Filing time
10 Jun 2022, 09:05:15 UTC
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OPTN Common Stock 42,196 10 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 42,758 $3.05 Direct F2
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 18,879 $5.14 Direct F2
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 37,542 $16.00 Direct F2
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 35,000 $7.42 Direct F3
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 20,000 $5.41 Direct F4
holding OPTN Stock Option (Right to Buy) 10 Jun 2022 Common Stock 27,500 $3.51 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 19,387 shares of common stock and 22,809 unvested restricted stock units (RSU) representing the right to receive one share of common stock of Optinose, Inc. upon vesting of each such RSU, subject to continued service with the Issuer.
F2 All option shares are exercisable.
F3 The option vests and becomes exercisable over a four-year period commencing on February 28, 2019. Twenty-five percent (25%) of the option vested and became exercisable on February 28, 2020, with the balance vesting in equal annual installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.
F4 The option vests and becomes exercisable over a four-year period commencing on March 6, 2020. Twenty-five percent (25%) of the option vested and became exercisable on March 6, 2021, with the balance vesting in equal annual installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.
F5 The option vests and becomes exercisable over a four-year period commencing on March 4, 2021. Twenty-five percent (25%) of the option vested and became exercisable on March 4, 2022, with the balance vesting in equal annual installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney